Zeller Anja, Arras Margarete, Jurd Rachel, Rudolph Uwe
Institute of Pharmacology and Toxicology, University of Zürich, Winterthurerstr, 190, CH-8057 Switzerland.
BMC Pharmacol. 2007 Feb 24;7:2. doi: 10.1186/1471-2210-7-2.
Agents belonging to diverse chemical classes are used clinically as general anesthetics. The molecular targets mediating their actions are however still only poorly defined. Both chemical diversity and substantial differences in the clinical actions of general anesthetics suggest that general anesthetic agents may have distinct pharmacological targets. It was demonstrated previously that the immobilizing action of etomidate and propofol is completely, and the immobilizing action of isoflurane partly mediated, by beta3-containing GABAA receptors. This was determined by using the beta3(N265M) mice, which carry a point mutation known to decrease the actions of general anesthetics at recombinant GABAA receptors. In this communication, we analyzed the contribution of beta3-containing GABAA receptors to the pharmacological actions of isoflurane, etomidate and propofol by means of beta3(N265M) mice.
Isoflurane decreased core body temperature and heart rate to a smaller degree in beta3(N265M) mice than in wild type mice, indicating a minor but significant role of beta3-containing GABAA receptors in these actions. Prolonged time intervals in the ECG and increased heart rate variability were indistinguishable between genotypes, suggesting no involvement of beta3-containing GABAA receptors. The anterograde amnesic action of propofol was indistinguishable in beta3(N265M) and wild type mice, suggesting that it is independent of beta3-containing GABAA receptors. The increase of heart rate variability and prolongation of ECG intervals by etomidate and propofol were also less pronounced in beta3(N265M) mice than in wild type mice, pointing to a limited involvement of beta3-containing GABAA receptors in these actions. The lack of etomidate- and propofol-induced immobilization in beta3(N265M) mice was also observed in congenic 129X1/SvJ and C57BL/6J backgrounds, indicating that this phenotype is stable across different backgrounds.
Our results provide evidence for a defined role of beta3-containing GABAA receptors in mediating some, but not all, of the actions of general anesthetics, and confirm the multisite model of general anesthetic action. This pharmacological separation of anesthetic endpoints also suggests that subtype-selective substances with an improved side-effect profile may be developed.
临床上使用的全身麻醉药属于多种化学类别。然而,介导其作用的分子靶点仍未明确界定。全身麻醉药的化学多样性和临床作用的显著差异均表明,全身麻醉药可能具有不同的药理学靶点。先前已证明,依托咪酯和丙泊酚的制动作用完全由含β3的GABAA受体介导,而异氟烷的制动作用部分由其介导。这是通过使用β3(N265M)小鼠确定的,该小鼠携带一个已知会降低全身麻醉药在重组GABAA受体上作用的点突变。在本通讯中,我们借助β3(N265M)小鼠分析了含β3的GABAA受体对异氟烷、依托咪酯和丙泊酚药理作用的贡献。
与野生型小鼠相比,β3(N265M)小鼠中异氟烷降低核心体温和心率的程度较小,表明含β3的GABAA受体在这些作用中起次要但重要的作用。心电图中的时间间隔延长和心率变异性增加在不同基因型之间无差异,表明含β3的GABAA受体未参与其中。丙泊酚的顺行性遗忘作用在β3(N265M)小鼠和野生型小鼠中无差异,表明其与含β3的GABAA受体无关。依托咪酯和丙泊酚引起的心率变异性增加和心电图间期延长在β3(N265M)小鼠中也比野生型小鼠中不明显,表明含β3的GABAA受体在这些作用中的参与有限。在同基因的129X1/SvJ和C57BL/6J背景中也观察到β3(N265M)小鼠中缺乏依托咪酯和丙泊酚诱导的制动作用,表明该表型在不同背景下是稳定的。
我们的结果为含β3的GABAA受体在介导全身麻醉药的部分而非全部作用中发挥明确作用提供了证据,并证实了全身麻醉作用的多位点模型。麻醉终点的这种药理学分离还表明,可能开发出副作用更小的亚型选择性物质。